title: [The European Commission approves the use of adalimumab for children ages 4 to 12].
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Avit
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005062:European Union; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab